Cytokinetics aims to become the Vertex of cardiovascular disease
But a surprise adcom for omecamtiv mecarbil might put a spanner in the works.
ACC 2022 – Bristol's rare hit could justify Myokardia
Mavacamten prevails again, but the big question for Bristol is the commercial opportunity.
Cytokinetics hopes to resurrect omecamtiv
Almost in stealth mode, Cytokinetics has pressed on with the heart failure project, which now awaits a key regulatory catalyst.
Biogen leads the amyotrophic lateral sclerosis hopefuls
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
